{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:51:35Z","timestamp":1769475095102,"version":"3.49.0"},"reference-count":20,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2014,10,17]],"date-time":"2014-10-17T00:00:00Z","timestamp":1413504000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["openrheumatologyjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TORJ"],"published-print":{"date-parts":[[2014,10,17]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives :<\/jats:title>\n                    <jats:p> To investigate differences in response to tumor necrosis factor inhibitor treatment (TNFi) in seropositive (rheumatoid factor positive; RF+) <jats:italic>versus<\/jats:italic> seronegative (RF-) patients with established RA as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) and pain.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Methods :<\/jats:title>\n                    <jats:p> RA patients from an established RA cohort were studied according to rheumatoid factor (RF) status for change in HAQ-DI and pain (0-3 VAS) one year after starting treatment with a TNFi.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Results :<\/jats:title>\n                    <jats:p> There were 238 patients treated with TNFi who had follow-up data (178 RF+ and 60 RF-). Disease duration was longer in RF+ <jats:italic>vs <\/jats:italic>RF- (12<jats:underline>+<\/jats:underline>8 <jats:italic>vs <\/jats:italic>8<jats:underline>+<\/jats:underline>8 years) but the proportion of females (82% <jats:italic>vs <\/jats:italic>72%, P=0.7), baseline HAQ-DI (1.44<jats:underline>+<\/jats:underline>0.63 <jats:italic>vs <\/jats:italic>1.41<jats:underline>+<\/jats:underline>0.63, P=0.8) and pain (1.92<jats:underline>+<\/jats:underline>0.67 <jats:italic>vs <\/jats:italic>1.93<jats:underline>+<\/jats:underline>0.67, P=0.9) were not different. The mean duration of treatment of first TNFi was 2.8 <jats:italic>vs <\/jats:italic>2.3 years, P=0.1 and 68% of RF+ <jats:italic>vs <\/jats:italic>62% of RF- were still receiving first TNFi at last visit (P=0.5). For patients with data at baseline and one year, the one-year HAQ-DI change was significantly greater in 90 RF+ patients (-0.356) <jats:italic>versus<\/jats:italic> 38 RF- patients (-0.126; P=0.04). The mean pain improvement was also greater in 77 RF+ <jats:italic>vs <\/jats:italic>32 RF- patients (-0.725 <jats:italic>vs <\/jats:italic>-0.332 respectively; P=0.03). Numbers are small, data are missing and comorbidities, DAS28 and anti-CCP were not collected.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Conclusion :<\/jats:title>\n                    <jats:p> Despite limitations in the data, in established RA after failure of DMARDs, RF+ patients may be more responsive to TNFi therapy as measured by changes in HAQ-DI and pain.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Innovation :<\/jats:title>\n                    <jats:p> There may be a better response to TNFi in RA if RF positive for function and pain.<\/jats:p>\n                <\/jats:sec>","DOI":"10.2174\/1874312901408010073","type":"journal-article","created":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T03:06:25Z","timestamp":1414379185000},"page":"73-76","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid Factor"],"prefix":"10.2174","volume":"8","author":[{"given":"Babak","family":"Aberumand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian","family":"Barra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole Le","family":"Riche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew E","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Rohekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry","family":"Rohekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Bonner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet E","family":"Pope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/03009740802484846","volume":"38","author":"Verschueren P","year":"2009","unstructured":"Verschueren P, Esselens G, Westhovens R. \n                    Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis an observational study. \n                    Scand J Rheumatol  \n                    2009; \n                    38\n                    :  166-72.","journal-title":"Scand J Rheumatol."},{"key":"refR2","first-page":"316","volume":"34","author":"Makinen H","year":"2007","unstructured":"Makinen H, Kautiainen H, Hannonen P , et al. \n                    Sustained remission and reduced radiographic progression with combination disease modifying antirehumatic drugs in early rheumatoid arthritis. \n                    J Rheumatol  \n                    2007; \n                    34\n                    :  316-21.","journal-title":"J Rheumatol."},{"key":"refR3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2666","volume":"11","author":"Rubbert-Roth A","year":"2009","unstructured":"Rubbert-Roth A, Finckh A. \n                    Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy a critical review. \n                    Arthritis Res Ther  \n                    2009; \n                    11\n                    (Suppl 1\n        )\n                    :  S1.","journal-title":"Arthritis Res Ther."},{"key":"refR4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"Fries JF","year":"1980","unstructured":"Fries JF,  Spitz P, Kraines RG,  Holman HR. \n                    Measurement of patient outcomes in arthritis. \n                    Arthritis Rheum  \n                    1980; \n                    23\n                    :  137-45.","journal-title":"Arthritis Rheum."},{"key":"refR5","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.3899\/jrheum.081122","volume":"36","author":"Barra L","year":"2009","unstructured":"Barra L, Pope JE,  Payne M. \n                    Real-world anti-tumour necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis cost-effectiveness based on number needed to treat to improve health assessment questionnaire. \n                    J Rheumatol  \n                    2009; \n                    36\n                    :  1421-8.","journal-title":"J Rheumatol."},{"key":"refR6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/ard.2006.056390","volume":"66","author":"Farragher TM","year":"2007","unstructured":"Farragher TM,  Lunt M, Bunn DK,  Silman AJ,  Symmons DP. \n                    Early Functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis results from the Norfolk Arthritis Register. \n                    Ann Rheum Dis  \n                    2007; \n                    66\n                    :  486-92.","journal-title":"Ann Rheum Dis."},{"key":"refR7","first-page":"1851","volume":"29","author":"Yelin E","year":"2002","unstructured":"Yelin E, Trupin L, Wong B, Rush S. \n                    The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. \n                    J Rheumatol  \n                    2002; \n                    29\n                    :  1851-7.","journal-title":"J Rheumatol."},{"key":"refR8","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/ar93","volume":"2","author":"Goldbach-Mansky R","year":"2000","unstructured":"Goldbach-Mansky R, Lee J, McCoy A , et al. \n                    Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. \n                    Arthritis Res  \n                    2000; \n                    2\n                    :  236-43.","journal-title":"Arthritis Res."},{"key":"refR9","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1136\/ard.2009.122739","volume":"69","author":"Miriovsky BJ","year":"2010","unstructured":"Miriovsky BJ,  Michaud K, Thiele GM , et al. \n                    Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. \n                    Ann Rheum Dis  \n                    2010; \n                    69\n                    :  1292-7.","journal-title":"Ann Rheum Dis."},{"key":"refR10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/rheumatology\/keg184","volume":"42","author":"Bas S","year":"2003","unstructured":"Bas S, Genevay S, Meyer O, Gabay C. \n                    Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. \n                    Rheumatology (Oxford)  \n                    2003; \n                    42\n                    :  677-80.","journal-title":"Rheumatology (Oxford)."},{"key":"refR11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/rheumatology\/keg257","volume":"42","author":"Vittecoq O","year":"2003","unstructured":"Vittecoq O, Pouplin S, Krzanowska K , et al. \n                    Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. \n                    Rheumatology (Oxford)  \n                    2003; \n                    42\n                    :  939-46.","journal-title":"Rheumatology (Oxford)."},{"key":"refR12","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","volume":"67","author":"Emery P","year":"2008","unstructured":"Emery P, Keystone E, Tony HP , et al. \n                    IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biological results from a 24-week multicenter randomized placebo-controlled trial. \n                    Ann Rheum Dis  \n                    2008; \n                    67\n                    :  1516-23.","journal-title":"Ann Rheum Dis."},{"key":"refR13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2011-200170","volume":"71","author":"Tak PP","year":"2012","unstructured":"Tak PP,  Rigby W, Rubbert-Roth A , et al. \n                    Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis 2-year results from the randomized controlled trial IMAGE. \n                    Ann Rheum Dis  \n                    2012; \n                    71\n                    :  351-7.","journal-title":"Ann Rheum Dis."},{"key":"refR14","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/rheumatology\/ker010","volume":"50","author":"Klaasen R","year":"2011","unstructured":"Klaasen R, Cantaert T, Wiibrandts CA , et al. \n                    The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis an exploratory study. \n                    Rheumatology (Oxford)  \n                    2011; \n                    50\n                    :  1487-93.","journal-title":"Rheumatology (Oxford)."},{"key":"refR15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jbspin.2013.04.004","volume":"81","author":"Salgado E","year":"2014","unstructured":"Salgado E, Maneiro Jr,  Carmona L, Gomez-Reino J. \n                    Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis Systematic review and meta-analysis of observational studies. \n                    Joint Bone Spine  \n                    2014; \n                    81\n                    : 41-50.","journal-title":"Joint Bone Spine."},{"key":"refR16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1196\/annals.1398.034","volume":"11","author":"Bobbio-Pallavinci F","year":"2007","unstructured":"Bobbio-Pallavinci F, Caporali R, Alpini C, Moratti Montecucco C. \n                    Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients. \n                    Ann N Y Acad Sci  \n                    2007; \n                    11\n                    :  287-95.","journal-title":"Ann N Y Acad Sci."},{"key":"refR17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.semarthrit.2012.11.007","volume":"42","author":"Maneiro RJ","year":"2013","unstructured":"Maneiro RJ,  Salgado E, Carmona L, Gomex-Reino JJ. \n                    Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis Systematic review and meta-analysis. \n                    Semin Arthritis Rheum  \n                    2013; \n                    42\n                    :  9-17.","journal-title":"Semin Arthritis Rheum."},{"key":"refR18","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"Aletaha D","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ , et al. \n                    2010, rheumatoid arthritis classification criteria an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. \n                    Ann Rheum Dis  \n                    2010; \n                    69\n                    :  1580-8.","journal-title":"Ann Rheum Dis."},{"key":"refR19","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/1529-0131(199812)41:12<2211::AID-ART17>3.0.CO;2-O","volume":"41","author":"Reparon-Schuiit CC","year":"1998","unstructured":"Reparon-Schuiit CC,  van Esch WJ,  van Kooten C, Levarht EW,  Breedveld FC,  Verweij CL. \n                    Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients. \n                    Arthritis Rheum  \n                    1998; \n                    41\n                    :  2211-20.","journal-title":"Arthritis Rheum."},{"key":"refR20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2177\/jsci.33.135","volume":"33","author":"Nozaki Y","year":"2010","unstructured":"Nozaki Y, Nagare Y, Hino S , et al. \n                    Therapeutic strategy and significance of serum rheumatoid factor in patients with rheumatoid arthritis during infliximab treatment. \n                    Nihon Rinsho Meneki Gakkai Kaishi  \n                    2010; \n                    33\n                    :  135-41.","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi."}],"container-title":["The Open Rheumatology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V8\/TORJ-8-73\/TORJ-8-73.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V8\/TORJ-8-73\/TORJ-8-73.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V8\/TORJ-8-73\/TORJ-8-73.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T01:59:40Z","timestamp":1561082380000},"score":1,"resource":{"primary":{"URL":"https:\/\/openrheumatologyjournal.com\/VOLUME\/8\/PAGE\/73\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,17]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,10,17]]}},"alternative-id":["TORJ-8-73"],"URL":"https:\/\/doi.org\/10.2174\/1874312901408010073","relation":{},"ISSN":["1874-3129"],"issn-type":[{"value":"1874-3129","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2014-7-7","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-2","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-3","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}